期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 63, 期 12, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00732-19
关键词
pretomanid; PA-824; tuberculosis; pharmacokinetics; pharmacodynamics; mathematical modeling
资金
- National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), HHS [R01AI125454]
Pretomanid (PA-824) is a nitroimidazole in clinical testing for the treatment of tuberculosis. A population pharmacodynamic model for pretomanid was developed using a Bayesian analysis of efficacy data from two early bactericidal activity (EBA) studies, PA-824-CL-007 and PA-824-CL-010, conducted in Cape Town, South Africa. The two studies included 122 adult male and female participants with newly diagnosed pulmonary tuberculosis who received once-daily oral pretomanid doses of either 50, 100, 150, 200, 600, 1,000, or 1,200 mg for 14 days. The structural model described capacity-limited growth and saturable drug-induced bacterial killing with separate rate equations for sputum solid culture CFU counts and liquid culture time to positivity (TTP) that were linked through a time constant. The posterior population geometric means and interindividual variability coefficients of variation were, respectively, 0.152 +/- 0.013 log(10) CFU/ml sputum/day and 54% +/- 6% for the maximum kill rate constant, 770 +/- 140 ng/ml and 48% +/- 17% for the pretomanid half-maximum effect plasma concentration, and 20.4 +/- 1.0 h and 20.8% +/- 0.1% for the time constant of proportionality between the CFU and TTP rate equations. Model simulations showed once-daily pretomanid at 100, 200, and 300 mg attained 58, 73, and 80%, respectively, of an expected maximum 14-day EBA of 0.136 log 10 CFU/ml sputum/day. These results establish a pretomanid exposure-efficacy relationship with dual outcomes for CFU counts and TTP and with potential applications to dose optimization of pretomanid-containing regimens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据